Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?
Micrometastatic disease clearance is essential to prevent late relapse. This approach is often undertaken at centers in Ontario and the UK, though little data exists unfortunately due to TMT previously being used for older, cis-ineligible patients. Would ctDNA sway your decision?